Long-term efficacy and safety of pegvisomant therapy in acromegaly.

[1]  G. Vargas,et al.  Octreotide LAR treatment of acromegaly in “real life”: long-term outcome at a tertiary care center , 2015, Pituitary.

[2]  S. Gaztambide,et al.  Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study , 2014, Clinical endocrinology.

[3]  E. Laws,et al.  Acromegaly: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[4]  V. Toscano,et al.  Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes , 2013, Journal of experimental & clinical cancer research : CR.

[5]  M. Buchfelder,et al.  Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. , 2012, The Journal of clinical endocrinology and metabolism.

[6]  P. Chanson,et al.  Current management practices for acromegaly: an international survey , 2011, Pituitary.

[7]  R. K. Hutson,et al.  Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy , 2009 .

[8]  S. Ezzat,et al.  A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly , 2009, Clinical endocrinology.

[9]  M. Hartman,et al.  IGF-I measurements in the diagnosis of adult growth hormone deficiency , 2007, Pituitary.

[10]  A. J. van der Lely,et al.  Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. , 2007, The Journal of clinical endocrinology and metabolism.

[11]  M. Buchfelder,et al.  Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. , 2007, European journal of endocrinology.

[12]  J. A. Scarlett,et al.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist , 2001, The Lancet.

[13]  M. S. Tewart,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .

[14]  P. Black,et al.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. , 1998, The Journal of clinical endocrinology and metabolism.

[15]  E. Siris.  Management of Paget's disease of bone in the era of new and more potent bisphosphonates. , 1997, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.